Regen Biopharma Inc (RGBAD)

[trazbull]

repost of great info from the rgbp baord!!

Hema Xellerate aims to provide "natural" replacement of synthetic cytokines. Synthetic cytokines that stimulate bone marrow represent an $18 Billion market.
FDA has cleared IND and is reviewing Orphan status. Regen is now the world leader in this field.

"Estimated (phase 1) value 20-25 million" Increases with Orphan status.


dcellvac is currently under review of updated submission to the FDA. Regen is very confident of their submission. The FDA is addressing questions with Dr Santosh Kesari, head of John Wayne Cancer Center Nuero-Oncology program.
Regen's goal is to replicate Flexus-BMS $800 million transaction on the same IDO target.
FDA clearance 1st quarter 2017.

"Estimated (phase 1) value 50-100 million"


NR2F6 is their "GEM" with all tests to date extremely positive. Let me just include forward looking values based on company research in this field.

Time Estimate phase 1 value

NR2F6 Activators Q4 2017 500 million (plus)

NR2F6 Inhibitors Q4 2017 500 million (plus)

July 2014 Roche paid $750 million upfront and 1 Billion in milestones acquisition of Seragon, A phase 1 company working on nuclear receptor modulators. (same family as Regens NR2F6 gene target).

"THE VALUE OF REGEN STARTING TOMORROW IS UNDER $20 MILLION"

Or you guys can just listen to the folks who say a lot without saying anything.